
STIFEL 2026: Trace Neuroscience believes that a breakthrough in ALS will be due to restoring expression of a protein called UNC13A, which most ALS patients don't have sufficient due to genetic factors
Co-Founder and CEO Eric Green explains the role of UNC13A, and how UNC13A mRNA is improperly spliced for most ALS patients. Trace is currently running a UK/EU phase 1 study of its antisense oligonucleotide that aims to restore expression, and also concurrently an investigator led study in China.
Publisher
BiotechTV - News
Link
podcasters.spotify.com/pod/show/biotechtv4/episodes/STIFEL-2026-Trace-Neuroscience-believes-that-a-breakthrough-in-ALS-will-be-due-to-restoring-expression-of-a-protein-called-UNC13A--which-most-ALS-patients-dont-have-sufficient-due-to-genetic-factors-e3s8a34
Published
November 12, 2026
Duration
8 min
Format
Podcast
Category
Issues · Science
Source
RSS feed
Host
BiotechTV
BiotechTV - News
@biotechtvnews
#traceneurosciencebelieves #proteincalledunc13a #alspatientsdont #lifesciences
